3.236.221.156
dgid:
enl:
npi:0
-Advertisement-
-Advertisement-

Oculoplastics

Longer disease duration doesn’t seem to impact teprotumumab response in TED

Data from the OPTIC phase 3, 24-week randomized, double-masked, placebo-controlled treatment trial was used to assess long-term proptosis response in patients who received teprotumumab. The majority of patients on teprotumumab who responded to treatment (≥ 2 mm improvement in proptosis) maintained their response at week 72. Patients in the OPTIC trial...

Read More
-Advertisement-
-Advertisement-
-Advertisement-
By rd360stg
By rd360stg
-Advertisement-
-Advertisement-
-Advertisement-
-Advertisement-
-Advertisement-
-Advertisement-
-Advertisement-
-Advertisement-
-Advertisement-